Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 33

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 33
---
-party licensors and partners, and will continue to do so in the future, if one of our licensors or partners
is sued for infringing a third party’s intellectual property rights, our business, financial condition, operating results, and
prospects could suffer in the same manner as if we were sued directly. In addition to facing litigation risks, we have agreed to indemnify
certain third-party licensors and partners against claims of infringement caused by our proprietary technologies, and we have entered
or may enter into cost-sharing agreements with some our licensors and partners that could require us to pay some of the costs of patent
litigation brought against those third parties whether or not the alleged infringement is caused by our proprietary technologies. In
certain instances, these cost-sharing agreements could also require us to assume greater responsibility for infringement damages than
would be assumed just on the basis of our technology.

The
occurrence of any of the foregoing could adversely affect our business, financial condition, or operating results.

We
may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, or
other claims may be made against us, which could be expensive and time-consuming.

Competitors
may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file
infringement claims to stop third-party infringement or unauthorized use. This can be expensive and time-consuming, particularly for
a company of our size. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable
or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology
or that the factors necessary to grant an injunction against an infringer are not satisfied. An adverse determination of any litigation
or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or amended such that they
do not cover our clinical assets. Moreover, such adverse determinations could put our patent applications at risk of not issuing or issuing
with limited and potentially inadequate scope to cover our clinical assets or to prevent others from marketing similar products.

Interference,
derivation, or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with
respect to our patent applications or those of our licensors or potential partners. Litigation or USPTO proceedings brought by us may
fail or